Hirono Tsutsumi
Fukuoka, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
IFITM3-MET interaction drives osimertinib resistance through AKT pathway activation in EGFR-mutant non-small cell lung cancer.
Journal: Molecular cancer
Published: February 25, 2025
Enhanced HER2 internalization by clathrin-dependent endocytosis in non-small cell lung cancer positive for HER2 mutations.
Journal: British journal of cancer
Published: November 27, 2024
TP53 gain-of-function mutations promote osimertinib resistance via TNF-α-NF-κB signaling in EGFR-mutated lung cancer.
Journal: NPJ precision oncology
Published: September 11, 2023
Impact of increased plasma levels of calreticulin on prognosis of patients with advanced lung cancer undergoing combination treatment of chemotherapy and immune checkpoint inhibitors.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: March 28, 2023
Regulation of PD-L1 expression in non-small cell lung cancer by interleukin-1β.
Journal: Frontiers in immunology
Published: March 24, 2023
Mutant forms of EGFR promote HER2 trafficking through efficient formation of HER2-EGFR heterodimers.
Mutant forms of EGFR promote HER2 trafficking through efficient formation of HER2-EGFR heterodimers.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: September 01, 2022
Increased plasma levels of damage-associated molecular patterns during systemic anticancer therapy in patients with advanced lung cancer.
Journal: Translational lung cancer research
Published: February 04, 2021
Cytotoxic chemotherapeutic agents and the EGFR-TKI osimertinib induce calreticulin exposure in non-small cell lung cancer.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: December 07, 2020
Multiclonality and Radiosensitivity of Granulocyte-colony Stimulating Factor-Producing Lung Adenocarcinoma Positive for an Activating EGFR Mutation.
Journal: Clinical lung cancer
Published: May 19, 2019
Showing 1-10 of 10
Last Updated: 09/26/2026